NIHR UK RARE GENETIC DISEASE RESEARCH CONSORTIUM

COLLABORATION AGREEMENT FOR RESEARCH ON RARE GENETIC DISEASES

This Agreement dated 21st May 2013 and as Amended herein 25th July 2014 (First Amendment) is between

Birmingham Women's NHS Foundation Trust, Mindelsohn Way, Edgbaston, Birmingham B15 2TG (referred to as "Birmingham")

AND

University Hospitals Bristol NHS Foundation Trust, Marlborough Street, Bristol BS1 3NU (referred to as "Bristol")

AND

Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ (referred to as "Cambridge")

AND

Royal Devon and Exeter NHS Foundation Trust, Barrack Road, Exeter EX2 5DW (referred to as "Exeter")

AND

Leeds Teaching Hospitals NHS Trust, Trust Headquarters, St James's University Hospital, Beckett Street, Leeds LS9 7TF (referred to as "Leeds")

AND

University Hospitals of Leicester NHS Trust, Level 3, Balmoral Building, Leicester Royal Infirmary, Infirmary Square LE1 5WW (referred to as "Leicester")

AND

Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool L8 7SS (referred to as "Liverpool")

AND

Great Ormond Street Hospital For Children NHS Foundation Trust, London WC1N 3JH (referred to as "London - NE Thames")

AND

North West London Hospitals NHS Trust, Northwick Park Hospital, Watford Road, Harrow HA1 3UJ (referred to as "London – NW Thames)

AND

Guy's and St Thomas's NHS Foundation Trust (referred to as "London – SE Thames")

AND

St George's Healthcare NHS Trust, Blackshaw Road, Tooting, London SW17 0QT (referred to as "London – SW Thames")

AND

Central Manchester University Hospitals NHS Foundation Trust, Cobbett House, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL (referred to as "Manchester")

AND

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne NE7 7DN (referred to as "Newcastle")

AND

Nottingham University Hospitals NHS Trust, City Hospital Campus, Hucknall Road, Nottingham, Nottinghamshire NG5 1PB (referred to as "Nottingham")

AND

Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU (referred to as "Oxford")

AND

The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ (referred to as "The Royal Marsden")

AND

Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield S10 2TH (referred to as "Sheffield")

AND

University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD (referred to as "Southampton")

AND

Grampian Health Board, Summerfield House, 2 Eday Road, Aberdeen, AB15 6RE (referred to as "Aberdeen")

AND

Tayside Health Board, King's Cross Hospital, Clepington Road, Dundee, DD3 8EA (referred to as "Dundee")

AND

Lothian Health Board, Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG (referred to as "Edinburgh")

AND

Greater Glasgow Health Board , J B Russell House, Gartnavel Royal Hospital Campus, 1055 Great Western Road, Glasgow G12 0XH (referred to as "Glasgow")

AND

Belfast Health & Social Care Trust, Trust Headquarters, A Floor, Belfast City Hospital, Lisburn Road Belfast, BT9 7AB (referred to as "Belfast")

AND

Cardiff and Vale University Health Board , Whitchurch Hospital, Park Road, Whitchurch, Cardiff CF14 7XB (referred to as "Cardiff")

Which are collectively referred to as the "Parties" or individually referred to as a "Party"

The Parties are the host NHS Organisations of the Regional Genetics Network and major genetics referral centres and wish to agree to the following terms and conditions when carrying out certain research studies.

DEFINITIONS

1.1. The following words and phrases have the following meanings:

1.1.1. Chief Investigator	The person who takes overall responsibility for the design, conduct and reporting of a Study. A list of Chief Investigators shall be approved and maintained by the Network and circulated to the Parties R&D offices from time to time.
1.1.2. Lead Party	The Party who is the employer of or who takes responsibility for the Chief Investigator
1.1.3. Materials	Blood, saliva, DNA and previously collected tissue blocks
1.1.4. Participant	Patient or relative, who consents to take part in the Study. All references to Participants refer to those recruited at or through a Site.
1.1.5. Rare Genetic Disease	a disease caused by abnormalities in genes or chromosomes and that affects less than 5 in 10,000 of the general population
1.1.6. R&D Approval	Approval given by the applicable R&D office of one of the Parties in accordance with the criteria set out in Schedule 1
1.1.7. Protocol	the description of any Study with any amendment thereto that has been approved by the relevant NHS Research Ethics Committee.
1.1.8. Results	All discoveries, data, information, theories, methods, computer programs, format of presentations and applications of the same and all manifestations or expressions of the same in physical, chemical, biological, molecular, electronic or written form.
1.1.9. Site	Any premises occupied by a Party where Participants will be recruited to the Study.
1.1.10. Study	The research study being carried out by the Lead Party which meets the criteria anticipated by Clause 2 below

.

2. SCOPE OF THE AGREEMENT.

2.1. Subject to Clause 2.2, this Agreement will apply to Studies which are (i) intended to determine the underlying mechanisms and refine the phenotype of a Rare Genetic Disease and (ii) adopted onto the UKCRN Portfolio and the NIHR UK Rare Genetic Disease Research Consortium and (iii) sponsored by the Lead Party and (iv) limited to the collection of biological samples e.g. blood, saliva, DNA, previously collected tissue blocks and their associated data.

2.2. The following studies are considered to be beyond the scope of this Agreement: studies involving the administration of an investigational medicinal product, studies involving scans, or other NHS Services, studies involving the flow down of funding terms.

3. R&D APPROVAL

3.1 All parties shall comply with the Research Governance Framework for Health and Social Care, Second Edition, April 2005, or the Research Governance Framework for Health and Social Care in Wales, November 2001 or the Scottish Executive Health Department Research Governance Framework for Health and Community Care, Second Edition, February 2006 or the Research Governance Framework for Health and Social Care in Northern Ireland, December 2006 or the latest version of the relevant Research Governance Framework should it be revised and reissued.

3.2 Lead Party responsibilities are to complete the checklist in Schedule 1 for each Study.

3.3 Where the Lead Party has confirmed that it has completed the checklist in Schedule 1 for the Study, the Site shall aim to grant R&D approval within 3 working days. A Party which persistently fails to meet the deadlines shall be suspended from leading or participating in Studies under this Agreement.

4 OBLIGATIONS OF THE PARTIES

4.1 The Parties shall conduct the Study in accordance with the current version of the Protocol and the terms of all relevant regulatory permissions and approvals, including, but not limited to: the terms and conditions of the favourable opinion given by the relevant NHS Research Ethics Committee.

5 LIABILITIES AND INDEMNITY

5.1 Nothing in this clause 5 shall operate so as to restrict or exclude the liability of any Party in relation to death or personal injury caused by the negligence of that Party or its employees, students, consultants and subcontractors, including researchers, or to restrict or exclude any other liability of any Party which cannot be so restricted in law.

5.2 Each Party shall be responsible for its negligence in the performance or wilful breach of this agreement.

5.3 No Party shall be liable to another in contract, tort, breach of statutory duty or otherwise for any loss of profits, revenue, reputation, business opportunity, contracts, or any indirect, consequential or economic loss arising directly or indirectly out of or in connection with this Agreement.

6. CONFIDENTIALITY, DATA PROTECTION AND FREEDOM OF INFORMATION

6.1. Medical confidentiality

6.1.1. The Parties agree to adhere to the principles of medical confidentiality in relation to Participants. The Parties shall comply with the requirements of the common law of confidentiality, the Data Protection Act 1998 and, as appropriate, the NHS Confidentiality Code of Practice or the Scottish Executive Health Department NHS Code of Practice on Protecting Patient Confidentiality or the Confidentiality: Code of Practice for Health and Social Care in Wales or the Code of Practice on Protecting the Confidentiality of Service Users in Northern Ireland, (when implemented).

6.1.2. It is the expectation of the parties that pertinent findings from the Studies should be fed back to the Site;

6.1.3. Neither the Lead Party nor the Site shall disclose the identity of Participants to third parties without the prior written consent of the Participant except in accordance with the Data Protection Act 1998 or, as appropriate, the NHS Confidentiality Code of Practice or the Scottish Executive Health Department NHS Code of Practice on Protecting Patient Confidentiality or the Confidentiality; Code of Practice for Health and Social Care in Wales or the Code of Practice on Protecting the Confidentiality of Service Users in Northern Ireland, (when implemented).

6.2. Freedom of Information

6.2.1. Parties to this Agreement which are subject to the Freedom of Information Act 2000 (FOIA) or the Freedom of Information (Scotland) Act 2002 (FOI(S)A) and which receive a request under FOIA or FOI(S)A to disclose any information that belongs to another Party shall notify and consult that Party in accordance with clause 14, as soon as reasonably practicable, and in any event, not later than five working days after receiving the request.

6.2.2. The Parties acknowledge and agree that the decision on whether any exemption applies to a request for disclosure of recorded information under FOIA or FOI(S)A is a decision solely for the Party responding to the request.

6.2.3. Where the Party responding to an FOIA or FOI(S)A request determines that it will disclose information it will notify the other Party in writing, giving at least two working days notice of its intended disclosure.

6.3. Confidential information

6.3.1. Each Party agrees to ensure that information supplied to them under this Agreement and belonging to or licensed to the other Party and marked as confidential is treated as confidential.

6.3.2. Each Party agrees:

6.3.2.1. To ensure that any of their employees, students, consultants or sub-contractors who participate in the operation of the Study are made aware of, and abide by, the requirement of clause 6.3.

6.3.2.2. To use the confidential information solely in connection with the operation of the Agreement and not otherwise.

6.3.2.3. Not to disclose the confidential information in whole or in part to any person without the other Party's written consent.

6.3.3. The provision of clause 6.3 shall not apply to the whole or any part of the confidential information that is:

6.3.3.1. Lawfully obtained free of any duty of confidentiality.

6.3.3.2. Already in the possession of the Party receiving such information and which they can show from written records (other than as a result of a breach of clause 6.3.1 or 6.3.2).

6.3.3.3. In the public domain (other than as a result of a breach of clause 6.3.1 or 6.3.2).

6.3.3.4. Necessarily disclosed pursuant to a statutory obligation.

6.3.3.5. Disclosed with prior written consent of the other Party.

6.3.3.6. Necessarily disclosed by a Party by virtue of its status as a public authority in terms of the Freedom of Information Act 2000 or the Freedom of Information (Scotland) Act 2002.

6.4. The restrictions contained in clause 6.3 shall continue to apply after the termination of this Agreement for 10 years.

7. PUBLICITY & USE OF LOGOS

7.1. The Parties shall ensure that the consent forms for the Studies shall include acknowledgement of the NIHR UK Rare Genetic Disease Research Consortium and shall collaborate to provide a web page with information regarding the Studies.

7.2. No Party shall use the name, logo or registered image of the other Party(ies) or their employees in any publicity, advertising or press release without the prior written approval of an authorised representative of that Party.

7.3. The content and timing of any publicity, advertising or press release shall be agreed by all Parties involved in this Agreement or the Study as applicable, such agreement not to be unreasonably withheld.

8. PUBLICATION

8.1 Following completion of the Study, the Lead Party shall use all reasonable endeavours to ensure the appropriate publication or other dissemination of the conclusions of the Study in accordance with normal academic practice. The parties agree that the basic DNA sequences derived from the Studies shall be placed in the public domain as soon as is practical, without any fees, patents, licences or limitations on use, giving free and equal access to all.

8.2 Publications of the Results of any Study shall acknowledge the support of the NIHR UK Rare Genetic Disease Research Consortium, any funder of the Study and shall comply with UKCRN portfolio study requirements.

8.3 It is the expectation of the parties that every effort should be taken to avoid identification of individuals in any publication.

9. ACCESS TO SAMPLES AND/OR DATA

9.1. All parties shall collect, use, store and dispose of any Materials sent or received under this Agreement in accordance with the terms of the consent under which it was provided, the relevant ethics approvals and the terms of the Human Tissue Act.

9.2. The Lead Site shall be responsible for ensuring that any third party named in the Protocol to whom the Material will be sent acts in accordance with the content of this Agreement.

9.3. Residual Material which is collected from Participants in any Study and banked by any Party on completion of such Study should be made available to researchers subject to the terms of the consent and ethical approval and the NIHR UK Rare Genetic Disease Research Consortium access policy in place from time to time.

10. FINANCIAL AND SUPPLIES ARRANGEMENTS

10.1. The Parties do not anticipate that funding for research shall be transferred under this Agreement for the conduct of studies. The Parties shall be responsible for meeting their own costs for any Study save where specialist equipment is to be provided by the Lead Site. Such specialist equipment will be provided free of charge to the Site by the Lead Site.

11. TERM AND TERMINATION

11.1. This Agreement shall come into effect as of 1st April 2013 and shall be validly entered into upon signature of no fewer than two Parties but shall only be enforceable by and against those Parties who have provided signatures to this Agreement. The Agreement shall remain in effect for an initial period of three years, and shall be automatically renewed on a three yearly basis.

11.2. Any Party may withdraw from this Agreement for any reason by giving all the parties 3 months notice in writing. Such termination shall not be effective in respect of any Study which is still recruiting and the provisions of any R&D Approval granted by such withdrawing Party will remain in effect until completion of recruitment for that Study.

11.3. If they unanimously agree to do so, the other Parties may treat any Party as having withdrawn from this Agreement with immediate effect by giving notice to that Party if that Party is in persistent breach of any provision of this Agreement and (if it is capable of remedy) the breach has not been remedied within 30 days after receipt of written notice specifying the breach and requiring its remedy. In such case the provisions of any R&D Approval granted by such withdrawing Party will remain in effect until completion of recruitment for that Study.

11.4. The following clauses shall survive the termination or expiry of this Agreement: clauses 1, 5-9, 11.4 and 14.

12. GENERAL

12.1. No failure or delay by any Party to exercise any right under this Agreement will operate as a waiver of it, nor will any partial exercise preclude any future exercise of the same.

12.2. If any clause or part of this Agreement is found by any court, tribunal, administrative body or authority of competent jurisdiction to be illegal, invalid or unenforceable then that provision shall, to the extent required, be severed from this Agreement and shall be effective without, as far as possible, modifying any other clause or part of this Agreement and shall not affect any other provisions of this Agreement which shall remain in full force and effect.

12.3. Nothing in this Agreement shall confer or purport to confer on any third party any benefit or any right to enforce any term of this Agreement.

12.4. Any amendments to this Agreement shall be valid only if made in writing, agreed and signed by the Parties.

12.5. This Agreement including its Schedules contains the entire understanding between the Parties and supersedes all other agreements, negotiations, representations and undertakings, whether written or oral of prior date between the Parties relating to the Study, which is the subject of this Agreement. Nothing in this Agreement will, however, operate to limit or exclude any liability for fraud.

13 NOTICES

13.1 Any notice under this Agreement shall be in writing, signed by the relevant Party to the Agreement and delivered personally, by courier, by recorded delivery post, or by facsimile, providing evidence of receipt, but not by e-mail.

13.2 Notices to the Parties shall be delivered to the person and at the address specified in Schedule 2. A Party may change their contact for notices at any time by confirming to the other Parties in writing the details of the relevant person.

14 GOVERNING LAW

14.1 Subject to Clause 14.2 this Agreement shall be made and interpreted in accordance with the laws of England and Wales and the Parties submit to the exclusive jurisdiction of the courts of English and Wales.

14.2 A Party who is located in Scotland or Northern Ireland shall be entitled to apply their respective national laws for the purposes of any Study undertaken in accordance with this Agreement.

14.3 Any dispute arising from a Study where the Lead Party is located in Scotland or Northern Ireland shall be submitted to the Scottish or Northern Irish Courts as applicable.

Signatures can be provided on separate counterparts, each of which so executed and delivered shall be an original

Signed by the duly authorised representatives of the Parties

SIGNED ON BEHALF OF

Birmingham Women's NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

University Hospitals Bristol NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Cambridge University Hospitals NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Royal Devon and Exeter NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Leeds Teaching Hospitals NHS Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

University Hospitals of Leicester NHS Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Liverpool Women's NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Great Ormond Street Hospital For Children NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

North West London Hospitals NHS Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Guy's and St Thomas's NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

St George's Healthcare NHS Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Central Manchester University Hospitals NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

The Newcastle upon Tyne Hospitals NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Nottingham University Hospitals NHS Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Oxford University Hospitals NHS Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

The Royal Marsden NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Sheffield Children's NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

University Hospital Southampton NHS Foundation Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Grampian Health Board

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Tayside Health Board

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Lothian Health Board

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Greater Glasgow Health Board

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Belfast Health & Social Care Trust

.....	.....	.....	.....
Name	Position	Signature	Date

SIGNED ON BEHALF OF

Cardiff and Vale University Health Board

.....	.....	.....	.....
Name	Position	Signature	Date

SCHEDULE 1

The Template R&D Approval Checklist to be completed and signed off by Lead Party R&D Office.

NIHR UK Rare Genetic Disease Research Consortium

R&D Sign off Form

Study Title:

Lead Party:

IRAS Reference:

	Check	**Comment**	**Lead Party R&D Comments**
B1	PIS and Patient Documents	For single SSI studies this is a Study-wide check	
B2	Emergency Arrangements	For single SSI studies this is a Study-wide check	
CI	CI/PI	For single SSI studies this is a Study-wide check	
D1	Risks to Organisation	Study deviates only minimally from standard care and no additional risks are anticipated	
D2	Allocation of Responsibilities	Covered by Agreement	
D3	Insurance and Indemnity	Covered by Agreement	
D4	Finances	Agreement states there will be no financial or supplies arrangements	

D5	Support Departments	No resource implications for departments outside the clinical genetics service.	
		If other labs are required to be involved the impact is going to be fairly minimal, we would expect local sites to have a notification rather than approval process.	
D6	Facilities	For single SSI studies this is a Study-wide check	
E1	Risks to Researcher	Study deviates only minimally from standard care and no additional risks are anticipated.	
F1	Data Protection	Covered by Agreement	
F3	Mental Capacity Act Adults with Incapacity (Scotland) Act 2000 Applicable Acts for other devolved nations	Further assessment may be needed on a case by case basis	
F4	PI HR resources assessed	For single SSI studies this is a Study-wide check related to the CI	
F6	Compliance with any applicable laws and regulations	Local checks require that local HTA licences are in place and arrangements for compliance with the act are adequate. Covered by Agreement	

H1	Have you used RSS planning Tool for this study at this site	Lead site to decide whether to use or not. It does not seem necessary for an RSS to be completed and it is not appropriate for one to be completed at the study level.	
		Advise if RSS completed.	

We <insert Party>, acting on behalf of the Lead Party for this Study, hereby confirm the above checks have been satisfactorily completed, as per the Governance Report, with comments in the above table and confirm R&D approval has been granted.

Sign

Name

Title

Date

SCHEDULE 2

Notices

Party	Contact for Notices	
Birmingham Women's NHS Foundation Trust, Mindelsohn Way, Edgbaston, Birmingham B15 2TG	Name	Kelly Hard
	Title	Research & Development Manager
	Address	Research and Development Office K13 Norton Court Birmingham Women's Hospital Mindelsohn Way Edgbaston, Birmingham B15 2TG
	Email	Kelly.hard@bwhct.nhs.uk
	Telephone	0121 627 2766 0121 607 4689
University Hospitals Bristol NHS Foundation Trust, Marlborough Street, Bristol BS1 3NU	Name	Diana Benton
	Title	Head of Research and Innovation
	Address	University Hospitals Bristol NHS Foundation Trust, Level 3 Education Centre, Upper Maudlin Street, Bristol BS2 8AE
	Email	diana.benton@uhbristol.nhs.uk
	Telephone	0117 342 0233
Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ	Name	Mary Kasanicki
	Title	Solicitor Consultant
	Email	mary.kasanicki@addenbrookes.nhs.uk
	Telephone	01223 34923
Royal Devon and Exeter NHS Foundation Trust, Barrack Road, Exeter EX2 5DW	Name	Claire Ridler
	Title	CLRN Research Management & Governance Manager

	Address	Royal Devon & Exeter NHS Foundation Trust Department of Research & Development Noy Scott House, Barrack Road, Exeter EX2 5DW
	Email	Claire.ridler@nhs.net
	Telephone	01392 403041
Leeds Teaching Hospitals NHS Trust, Trust Headquarters, St James's University Hospital, Beckett Street, Leeds LS9 7TF	Name	Anne Gowing
	Title	Research Governance Manager
	Address	34 Hyde Street, Leeds LS2 9LN
	Email	anne.gowing@leedsth.nhs.uk
	Telephone	0113 39 22795
University Hospitals of Leicester NHS Trust, Level 3, Balmoral Building, Leicester Royal Infirmary, Infirmary Square LE1 5WW	Name	Dr David Hetmanski
	Title	Assistant Director of R&D
	Address	Research & Development Office, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW
	Email	david.hetmanski@uhl-tr.nhs.uk
	Telephone	0116 258 4199
Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool L8 7SS	Name	Gillian Vernon
	Title	Research & Development Manager
	Email	Gillian.vernon@lwh.nhs.uk
	Telephone	0151 702 4346
Great Ormond Street Hospital For Children NHS Foundation Trust, London WC1N 3JH	Name	Emma Pendleton
	Title	Deputy Director of Research & Innovation
	Address	Research & Development Office, Institute of Child Health, 30 Guilford Street, London WC1N 1EH

	Email	Emma.Pendleton@gosh.nhs.uk
	Telephone	0207 905 2700
North West London Hospitals NHS Trust, Northwick Park Hospital, Watford Road, Harrow HA1 3UJ	Name	Simon Lewis
	Title	Research Governance Manager
	Email	simon.lewis4@nhs.net
	Telephone	020 8869 5173
Guy's and St Thomas's NHS Foundation Trust, Great Maze Pond, London SE1 9RT	Name	Karen Ignatian
	Title	R&D Governance Manager
	Address	F16, Tower Wing, Guy's Hospital, Great Maze Pond, London SE1 9RT
	Email	Karen.ignatian@gstt.nhs.uk
	Telephone	020 7188 7188
St George's Healthcare NHS Trust, Blackshaw Road, Tooting, London SW17 0QT	Name	Nadia Azzouzi
	Title	Research Governance Officer
	Address	Joint Research Office(JRO) St George's University of London Cranmer Terrace, London SW17 0RE
	Email	nazzouzi@sgul.ac.uk
	Telephone	020 8725 1012
Central Manchester University Hospitals NHS Foundation Trust, Cobbett House, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL	Name	Lynne Webster
	Title	Head of Research Office
	Email	lynne.webster@cmft.nhs.uk
	Telephone	0161 276 3565
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne, NE7 7DN	Name	Amanda Tortice
	Title	Head, Newcastle Joint Research Office

	Address	Joint Research Office, Level 6, Leazes Wing, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP
	Email	Amanda.tortice@ncl.ac.uk
	Telephone	0191 282 5213
Nottingham University Hospitals NHS Trust, City Hospital Campus, Hucknall Road, Nottingham, Nottinghamshire NG5 1PB	Name	Dr Maria Koufali
	Title	Deputy Director of Research and Innovation
	Address	Research & Innovation, Nottingham University Hospitals NHS Trust, Nottingham Integrated Clinical Research Centre, C Floor, South Block, Queen's Medical Centre Campus, Derby Road Nottingham NG7 2UH
	Email	maria.koufali@nuh.nhs.uk
	Telephone	0115 970 9049
Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU	Name	Cynthia Ugochukwu
	Title	IP and Contracts Lead
	Address	Oxford University Hospitals NHS Trust, Joint Research Office, Block 60, Churchill Hospital Old Road, Headington, Oxford OX3 7LE
	Email	Cynthia.ugochukwu@admin.ox.ac.uk
	Telephone	01865 572202
The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ	Title	Clinical Trials Administrator
	Address	The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surry SM2 5PT
	Email	research.development@rmh.nhs.uk
	Telephone	020 8661 3873
Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield S10 2TH	Name	Wendy Swann
	Title	Research & Development Manager
	Email	wendy.swann@sch.nhs.uk
	Telephone	0114 22 60507

University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD	Name Heidi Nield Title Acting Head of Research and Development Address R&D Office, E Level, Southampton Centre for Biomedical Research Laboratory and Pathology Block, Mailpoint 138 Southampton General Hospital Tremona Road Southampton SO16 6YD Email Heidi.nield@uhs.nhs.uk Telephone 02380 795131
Grampian Health Board, Summerfield House, 2 Eday Road, Aberdeen, AB15 6RE	Name Dr Susan Ridge Title Non Commercial Research Manager Address Research&Development, Forresterhill House Annexe, Forresterhill, Aberdeen, AB25 2ZB Email s.ridge@nhs.net Telephone 01224 553728
Tayside Health Board, King's Cross Hospital, Clepington Road, Dundee, DD3 8EA	Name Liz Coote Title R&D Manager Address Tayside Medical Science Centre TASC Research & Development Office Ninewells Hospital & Medical School Residency Block, Level 3 George Pirie Way Dundee, DD1 9SY Email liz.coote@nhs.net Telephone 01382 383876
Lothian Health Board, Waverley Gate, 2-4 Waterloo Place, Edinburgh, EH1 3EG	Name Dr Douglas Young Title Principal R&D Manager

	Address Research & Development Management Suite The Queen's Medical Research Institute 47 Little France Crescent Edinburgh EH16 4TJ E mail douglas.young@luht.scot.nhs.uk Telephone 0131 242 3337
Greater Glasgow Health Board , J B Russell House, Gartnavel Royal Hospital Campus, 1055 Great Western Road, Glasgow G12 0XH	Name Dr Nathaniel Brittain Title Academic Research Coordinator Address Research & Development Management Office NHS Greater Glasgow & Clyde The Tennent Institute Western Infirmary 38 Church Street Glasgow G11 6NT Email Nathaniel.Brittain@ggc.scot.nhs.uk Telephone 0141 211 8544
Belfast Health & Social Care Trust, Trust Headquarters, A Floor, Belfast City Hospital, Lisburn Road Belfast, BT9 7AB	Name Alison Murphy Title R&D Manager Address Research & Development Office, Belfast Health & Social Care Trust, Room 2010, 2nd Floor, King Edward Building, Royal Hospitals Site, Grosvenor Road, Belfast, BT12 6BA Email Alison.Murphy@belfasttrust.hscni.net Telephone 028 9063 6366
Cardiff and Vale University Health Board , Whitchurch Hospital, Park Road, Whitchurch, Cardiff CF14 7XB	Name Emma Lewis Title R&D Manager Address Cardiff & Vale UHB R&D Office 2nd Floor TB2, Room 1, University Hospital Wales, Health Park, Cardiff, CF14 4XW Email Emma.Lewis6@wales.nhs.uk Telephone 029 2074 6989